298 related articles for article (PubMed ID: 38542151)
1. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD; Are C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
[TBL] [Abstract][Full Text] [Related]
2. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.
Sanaei MJ; Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Shahrokh S; Zali MR; Bashash D
J Cell Physiol; 2022 Mar; 237(3):1720-1752. PubMed ID: 34897682
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
4. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
5. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
Narayanankutty A
Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
[TBL] [Abstract][Full Text] [Related]
6. B7-H4 facilitates proliferation and metastasis of colorectal carcinoma cell through PI3K/Akt/mTOR signaling pathway.
Li C; Zhan Y; Ma X; Fang H; Gai X
Clin Exp Med; 2020 Feb; 20(1):79-86. PubMed ID: 31664539
[TBL] [Abstract][Full Text] [Related]
7. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway.
Yin F; Huang X; Xuan Y
Dis Markers; 2021; 2021():9950663. PubMed ID: 34512817
[TBL] [Abstract][Full Text] [Related]
8. HOTAIR/miR-326/FUT6 axis facilitates colorectal cancer progression through regulating fucosylation of CD44 via PI3K/AKT/mTOR pathway.
Pan S; Liu Y; Liu Q; Xiao Y; Liu B; Ren X; Qi X; Zhou H; Zeng C; Jia L
Biochim Biophys Acta Mol Cell Res; 2019 May; 1866(5):750-760. PubMed ID: 30742932
[TBL] [Abstract][Full Text] [Related]
9. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
Yu L; Wei J; Liu P
Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
[TBL] [Abstract][Full Text] [Related]
10. To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway.
Zhong J; Ding S; Zhang X; Di W; Wang X; Zhang H; Chen Y; Zhang Y; Hu Y
Front Biosci (Landmark Ed); 2023 Feb; 28(2):37. PubMed ID: 36866550
[TBL] [Abstract][Full Text] [Related]
11. [LncRNA SNHG11 promotes malignant progression of colorectal cancer cells through the PI3K/Akt/mTOR signaling pathway].
Tao SN; Liu XC; Wang YY; Yang H
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):758-765. PubMed ID: 38462356
[No Abstract] [Full Text] [Related]
12. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
[TBL] [Abstract][Full Text] [Related]
13. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
14. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways.
Duan S; Huang W; Liu X; Liu X; Chen N; Xu Q; Hu Y; Song W; Zhou J
J Exp Clin Cancer Res; 2018 Dec; 37(1):304. PubMed ID: 30518405
[TBL] [Abstract][Full Text] [Related]
15. MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway.
Su W; Feng B; Hu L; Guo X; Yu M
BMC Cancer; 2022 Jun; 22(1):602. PubMed ID: 35655161
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer.
Moafian Z; Maghrouni A; Soltani A; Hashemy SI
Mol Biol Rep; 2021 May; 48(5):4797-4811. PubMed ID: 34057685
[TBL] [Abstract][Full Text] [Related]
17. Recent clinical advances in PI3K inhibitors on colorectal cancer.
Zhu M; Jin Q; Xin Y
Pharmazie; 2021 Dec; 76(12):568-573. PubMed ID: 34986950
[TBL] [Abstract][Full Text] [Related]
18. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressive effect of scavenger receptor class A member 5 overexpression in colorectal cancer by regulating PI3K/AKT/mTOR pathway.
Li Y; Peng F; Tan X; Wang J; Xu Y
Genes Genomics; 2021 Oct; 43(10):1189-1198. PubMed ID: 34417976
[TBL] [Abstract][Full Text] [Related]
20. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
